Donny Wong Ph.D., principal analyst at Decision Resources, is available to discuss diabetes-related findings that will be announced during the American Diabetes Association's 68th Scientific Sessions being held June 6-10, 2008 in San Francisco.
Dr. Wong can discuss: -- General questions about the size and scope of the pharmaceutical market for diabetes therapies and the market impact of the following emerging drug classes: SGLT-2 inhibitors, DPP-IV inhibitors and GLP-1 analogues -- Presentations at the ADA conference of the full reports from the following clinical trials: the ACCORD Study, the ADVANCE Study and the VA Diabetes Trial. -- The market potential for novel non-injectable insulin formulations that remain in development following the suspension of development of inhaled insulins by Eli Lilly and Novo Nordisk -- The ongoing impact on the sales of Avandia following the publication of a meta-analysis that questions the cardiovascular safety of the drug -- The recent filing by Novo Nordisk for regulatory approval in the United States and Europe of liraglutide for the treatment of type 2 diabetes
To speak with Dr. Wong, please contact Liz Marshall at 781-296-2563 or email@example.com.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall 781-296-2563 firstname.lastname@example.org
PRNewswire -- June 4
SOURCE: Decision Resources